The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical ...

Buildings A and B are part of the second phase of Provident's Plano Commerce Center developments. Phase II consists of three ...

If you continue to have this issue please contact [email protected]. The phase 2 clinical trial investigated PA5108 (latanoprost, PolyActiva) for 48 weeks, during which it showed ...

Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation ("GPCR"), pursuant to ...

Ora Dental Implant Studio has been honored as a Top Patient Rated Elk Grove Dentist for 2025, a testament to the clinic's commitment to excellence in dental care. Find Local Doctors is a trusted ...

ORTHO-R is under clinical development by ChitogenX and currently in Phase II for Unspecified Musculoskeletal Disorders.

Neuroprosthetics research has entered a stage in which animal models and proof-of-concept studies are translated into ...

Glaukos GKOS recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical ...

In addition to SPC-15, we are advancing development of our SP-26 ketamine implant and ... the FDA on the 505(b)(2) regulatory pathway for approval of SPC-15 as we prepare for an expected IND ...

NYSE:GKOS) Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform ...

Ocular Therapeutix's OTX-TKI implant offers a cost-effective ... Recent FDA approval for trial modifications and positive phase 1 results in NPDR patients enhance OTX-TKI's potential, with ...